Full text loading...
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Comparison of seed loading approaches in prostate brachytherapy
1.J. C. Blasko, P. D. Grimm, and H. Ragde, “Brachytherapy and organ preservation in the management of carcinoma of the prostate,” Sem. Rad. Oncol. 3, 240–249 (1993).
2.K. Wallner, J. Roy, and L. Harrison, “Tumor control and morbidity following transperineal I-125 implantation for stage prostatic carcinoma,” J. Clin. Oncol. 14, 449–453 (1996).
3.M. Dattoli et al., “Pd-103 brachytherapy and external beam radiation therapy for clinically localized high risk prostatic carcinoma,” Int. J. Radiat. Oncol., Biol., Phys. 35, 875–879 (1996).
4.H. Ragde, J. C. Blasko, P. D. Grimm, G. M. Kenny, J. E. Sylvester, D. C. Hoak, K. Landin, and W. Cavanagh, “Interstitial I-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer,” Cancer (N.Y.) 80, 442–453 (1997).
5.H. Ragde, J. C. Blasko, P. D. Grimm, G. M. Kenny, J. Sylvester, D. C. Hoak, W. Cavanagh, and K. Landin, “Brachytherapy for clinically localized prostate cancer: Results at 7 and 8 year follow-up,” Sem. Surg. Oncol. 13, 438–443 (1997).
6.H. Ragde, A. A. Elgamal, P. B. Snow, J. Brandt, A. A. Bartolucci, B. S. Nadir, and L. J. Korb, “Ten year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma,” Cancer (N.Y.) 83, 989–1001 (1998).
7.P. D. Grimm, J. C. Blasko, and H. Ragde, “Ultrasound guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer,” Atlas. Urol. Clin. N. Am. 2, 113–125 (1994).
8.J. N. Roy, C. C. Ling, K. E. Wallner, and L. L. Anderson, “Determining source strength and source distribution for a transperineal prostate implant,” Endocurietherapy/Hyperthermia Oncol. 12, 35–42 (1996).
9.R. Nath, L. L. Anderson, J. A. Meli, A. J. Olch, J. A. Stitt, and J. F. Williamson, “Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56,” Med. Phys. 24, 1557–1598 (1997).
10.G. S. Merrick, W. M. Butler, A. T. Dorsey, and H. L. Walbert, “Prostatic conformal brachytherapy: I-125/Pd-103 post-operative dosimetric analysis,” Radiat. Oncol. Invest. 5, 305–313 (1997).
11.G. S. Merrick, W. M. Butler, A. T. Dorsey, and H. L. Walbert, “The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy,” Radiat. Oncol. Invest. 6, 182–190 (1998).
12.K. Wallner, J. Roy, and L. Harrison, “Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 32, 465–471 (1995).
13.N. N. Stone and R. G. Stock, “Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation,” Tech. Urol. 1, 72–80 (1995).
14.A. W. Partin, M. W. Kattan, E. N. Subong, P. C. Walsh, K. J. Wojno, J. E. Oesterling, P. T. Scardino, and J. D. Pearson, “Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update,” J. Am. Med. Assoc. 277, 1445–1451 (1997).
15.P. L. Roberson, V. Narayana, D. L. McShan, R. J. Winfield, and P. W. McLaughlin, “Source placement error for permanent implant of the prostate,” Med. Phys. 24, 251–257 (1997).
16.G. S. Merrick, W. M. Butler, A. T. Dorsey, and J. H. Lief, “The potential role of various dosimetric quality indicators in prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 44, 717–724 (1999).
17.E. M. Tapen, J. C. Blasko, P. D. Grimm, H. R. Ragde, R. Luse, S. Clifford, J. Sylvester, and T. W. Griffin, “Reduction of radioactive seed embolization to the lung following prostate brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. 42, 1063–1067 (1998).
18.G. S. Merrick, W. M. Butler, A. T. Dorsey, J. H. Lief, and M. L. Benson, “Seed fixity in the prostate/periprostatic region following brachytherapy,” Int. J. Radiat. Oncol., Biol., Phys. (in press).
19.G. S. Merrick, W. M. Butler, A. T. Dorsey, and H. L. Walbert, “Prostatic conformal brachytherapy: I-125/Pd-103 post-operative dosimetric analysis,” Radiat. Oncol. Invest. 5, 305–313 (1997).
20.F. Waterman and A. Dicker, “Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the post-implant CT scan,” Med. Phys. (in press).
21.C. C. Ling, J. Roy, N. Sahoo, K. Wallner, and L. Anderson, “Quantifying the effect of dose inhomogeneity in brachytherapy: Application to permanent prostatic implant with seeds,” Int. J. Radiat. Oncol., Biol., Phys. 28, 971–978 (1994).
22.K. Wallner, H. Lee, S. Wasserman, and M. Dattoli, “Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection,” Int. J. Radiat. Oncol., Biol., Phys. 37, 565–569 (1997).
23.R. G. Stock, N. N. Stone, A. Tabert, C. Iannuzzi, and J. K. DeWyngaert, “A dose response study for I-125 prostate implants,” Int. J. Radiat. Oncol., Biol., Phys. 41, 101–108 (1998).
Article metrics loading...